Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Roflumilast in Psoriasis of nail: NCT07725822 Clinical Landscape Report 2026
16 September 2026
NCT07725822 clinical landscape for Psoriasis of nail: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iberdomide in Relapse multiple myeloma: NCT07727668 Clinical Landscape Report 2026
16 September 2026
NCT07727668 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD30.CAR-EBVST cell therapy(Baylor College of Medicine) in Hodgkin's Lymphoma: NCT07729397 Clinical Landscape Report 2026
16 September 2026
NCT07729397 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MTAI-1025 in Digestive System Disorders: ACTRN12626000920392 Clinical Landscape Report 2026
16 September 2026
ACTRN12626000920392 clinical landscape for Digestive System Disorders: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Ebastine in Hepatocellular Carcinoma: NCT07734766 Clinical Landscape Report 2026
16 September 2026
NCT07734766 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Docosahexaenoic acid in Multiple Sclerosis: ACTRN12626000924358 Clinical Landscape Report 2026
16 September 2026
ACTRN12626000924358 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Ovarian Cancer: NCT07733505 Clinical Landscape Report 2026
16 September 2026
NCT07733505 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mepolizumab in Pulmonary Disease, Chronic Obstructive: ISRCTN17701271 Clinical Landscape Report 2026
16 September 2026
ISRCTN17701271 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
ZP-9830 in Plaque psoriasis: NCT07733089 Clinical Landscape Report 2026
16 September 2026
NCT07733089 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Isatuximab-IRFC in Multiple Myeloma: NCT07732712 Clinical Landscape Report 2026
16 September 2026
NCT07732712 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Endometrial Carcinoma: ACTRN12626000937314 Clinical Landscape Report 2026
16 September 2026
ACTRN12626000937314 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Envafolimab in Hepatocellular Carcinoma: NCT07738055 Clinical Landscape Report 2026
16 September 2026
NCT07738055 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.